Ozempic Pill: Ozempic Tablets, Rybelsus and the Wegovy Pill Explained

The Ozempic pill is a once-daily semaglutide tablet for adults with type 2 diabetes. On February 4, 2026, the FDA approved the name Ozempic for Novo Nordisk’s newer oral semaglutide formulation, sold in 1.5, 4 and 9 mg tablets, and it reached U.S. pharmacies on May 4, 2026. It replaces Rybelsus, the original semaglutide tablet approved in 2019, which shares its label. The Ozempic pill is not the Wegovy pill: Ozempic tablets are for type 2 diabetes, while Wegovy tablets are for weight management. This guide explains the rename, Rybelsus vs Ozempic, how oral semaglutide is taken and what the trials found.

Peptide Labs does not sell Ozempic, Rybelsus, Wegovy or any prescription drug. This article is general information, not medical advice. All three are prescription-only.

What is the Ozempic pill?

Ozempic started in 2017 as a once-weekly semaglutide injection for type 2 diabetes. In 2019 Novo Nordisk added a daily semaglutide tablet under a different name, Rybelsus, in 3, 7 and 14 mg strengths. It later developed a second tablet formulation that contains inactive ingredients that improve absorption, so the same effect needs fewer milligrams. The FDA approved that newer tablet under the Ozempic brand, giving the injection and the pill one familiar name. According to a Medical Letter review from April 2026, Rybelsus tablets will remain available for some time so patients can switch.

Both tablets now share one prescribing information document, most recently revised in January 2026. It approves them, alongside diet and exercise, to improve blood sugar control in adults with type 2 diabetes, and to lower the risk of cardiovascular death, heart attack and stroke in adults with type 2 diabetes at high risk of those events, an indication added in October 2025. Neither tablet is approved for weight management or for children. For the molecule, see our semaglutide profile.

Rybelsus vs Ozempic tablets vs Ozempic injection

The label states plainly that Rybelsus and Ozempic tablets are not substitutable on a milligram-to-milligram basis, and it gives prescribers separate instructions for switching between them and for switching from the Ozempic injection to a tablet. Anyone moving between products should follow the prescriber’s and pharmacist’s directions rather than matching numbers.

Ozempic pill vs Wegovy pill

The two pills contain the same drug but belong to different brands with different purposes:

• Ozempic tablets: type 2 diabetes and cardiovascular risk reduction in type 2 diabetes; 1.5, 4 and 9 mg.
• Wegovy tablets: long-term weight management in adults with obesity, or overweight with a weight-related condition, and cardiovascular risk reduction in adults with heart disease and obesity or overweight. Approved December 22, 2025, in strengths up to a 25 mg maintenance tablet.

So when people search for an “Ozempic pill for weight loss”, the approved product for that purpose is actually the Wegovy pill. In the OASIS 4 trial, adults without diabetes on Wegovy tablets lost 13.6% of body weight on average over 64 weeks, versus 2.2% on placebo. Our Wegovy pill guide covers that approval, and Wegovy vs Ozempic compares the two brands overall.

How the Ozempic pill is taken

Semaglutide is a peptide, and very little of a swallowed peptide survives digestion. The tablets use an absorption enhancer, and even so the label estimates that only about 1% to 2% of an Ozempic tablet and 0.4% to 1% of a Rybelsus tablet reaches the bloodstream. Food and other drinks cut that further, so the label has strict rules. In general terms, the tablet is taken once a day in the morning on an empty stomach, with only a small amount of plain water, swallowed whole, and followed by a waiting period before eating, drinking anything else or taking other oral medicines. The Medication Guide and pharmacist give the exact instructions, including what to do about a missed tablet.

Because semaglutide slows stomach emptying, it can also change how other oral medicines are absorbed, so the label advises closer monitoring for medicines that need precise blood levels. A full medication list for the prescriber and pharmacist matters here.

What the trials found: PIONEER and SOUL

Oral semaglutide was developed in the PIONEER trial program, which compared the tablets with placebo and with other diabetes drugs, including empagliflozin, sitagliptin and liraglutide, and tested them in people with kidney impairment. Two cardiovascular trials stand out:

• PIONEER 6 (New England Journal of Medicine, 2019) enrolled 3,183 adults with type 2 diabetes at high cardiovascular risk. Over a median of about 16 months, major cardiovascular events occurred in 3.8% on oral semaglutide and 4.8% on placebo, which showed the tablet did not increase risk but was not designed to prove a reduction.
• SOUL (New England Journal of Medicine, 2025) enrolled 9,650 adults aged 50 or older with type 2 diabetes and heart disease, chronic kidney disease or both. Over a median of about four years, major cardiovascular events occurred in 12.0% on oral semaglutide versus 13.8% on placebo, a 14% lower relative risk. This trial is the basis for the tablets’ October 2025 cardiovascular indication.

Both trials used the original Rybelsus formulation and were funded by Novo Nordisk. The company says the newer Ozempic tablets work similarly to the original strengths, with the same efficacy and safety profile in a smaller pill.

Side effects and warnings

Side effects of the tablets mirror those of the injection. In the label’s pooled placebo-controlled trials, nausea affected 11% to 20% of people on the tablets versus 6% on placebo, and digestive side effects overall were most common while the dose was being increased. The label carries the same boxed warning about thyroid C-cell tumors seen in rodents, and warnings about pancreatitis, diabetic eye complications, low blood sugar with insulin or a sulfonylurea, kidney injury from dehydration, severe digestive reactions, allergic reactions, gallbladder disease and anesthesia. It advises stopping at least two months before a planned pregnancy and does not recommend breastfeeding. Our semaglutide side effects guide compares all the semaglutide labels. Lilly’s oral option, Foundayo, is a different molecule with no empty-stomach rules.

Frequently Asked Questions

This article is general information, not medical advice. Peptide Labs does not sell prescription drugs, including any product named here. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.

Last reviewed September 2026.